Stadie T R, Chai W, Lawson A M, Byfield P G, Hanisch F G
Institute of Immunobiology, University Clinic, Cologne, Germany.
Eur J Biochem. 1995 Apr 1;229(1):140-7.
A synthetic peptide [TAP25, (T1aAPPAHGVT9S10APDT14RPAPGS20)T1bAPPA5b] corresponding to one repeat (T1a-S20) and five overlapping amino acids (T1b-A5b) of the MUC1 core protein served as an acceptor substrate for in vitro glycosylation. TAP25 was glycosylated using the detergent-solubilized UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases from the breast carcinoma cell line T47D, the colon carcinoma cell line HT29 and from human premature skim milk. The glycosylated peptides were isolated by ultrafiltration, purified by reverse-phase HPLC and further analysed by liquid secondary ion mass spectrometry (LSIMS). Three different glycosylation species, mono-, di- and triglycosylated peptides were identified. Automated Edman sequencing and LSIMS of proteolytic fragments independently revealed the sites of GalNAc incorporation and confirmed that the threonine residues Thr9 and Thr1b are the preferred sites of glycosylation independent of the enzyme source, while Thr14 remained non-glycosylated even with the enzyme preparation from milk. In addition, evidence was obtained that at least 20% of the glycosylated peptides exhibited GalNAc incorporation at Ser20. On the basis of kinetic studies a preferred sequence of GalNAc addition to the three acceptor sites has been concluded (Thr9-->Thr1b-->Ser20). Although Thr14 within the PDTRP motif of the tandem repeats remained non-glycosylated, the introduction of GalNAc into adjacent positions significantly decreased the immunoreactivity of antibodies SM-3, HMFG-1 and HMFG-2 defining overlapping epitopes of this motif. It is assumed that glycosylation at Thr9, Thr1b and Ser20 distorts the peptide conformation of the binding epitope.
一种合成肽[TAP25,(T1aAPPAHGVT9S10APDT14RPAPGS20)T1bAPPA5b],对应于MUC1核心蛋白的一个重复序列(T1a - S20)和五个重叠氨基酸(T1b - A5b),用作体外糖基化的受体底物。使用来自乳腺癌细胞系T47D、结肠癌细胞系HT29以及人早产脱脂乳中经去污剂溶解的UDP - GalNAc:多肽N - 乙酰半乳糖胺基转移酶对TAP25进行糖基化。通过超滤分离糖基化肽,经反相高效液相色谱纯化,再用液体二次离子质谱(LSIMS)进一步分析。鉴定出三种不同的糖基化形式,即单糖基化、双糖基化和三糖基化肽。对蛋白水解片段进行自动Edman测序和LSIMS分析,独立揭示了GalNAc掺入位点,并证实苏氨酸残基Thr9和Thr1b是与酶来源无关的糖基化优选位点,而即使使用来自牛奶的酶制剂,Thr14仍未糖基化。此外,有证据表明至少20%的糖基化肽在Ser20处有GalNAc掺入。基于动力学研究得出了GalNAc添加到三个受体位点的优选顺序(Thr9→Thr1b→Ser20)。虽然串联重复序列的PDTRP基序内的Thr14仍未糖基化,但在相邻位置引入GalNAc显著降低了定义该基序重叠表位的抗体SM - 3、HMFG - 1和HMFG - 2的免疫反应性。据推测,Thr9、Thr1b和Ser20处的糖基化使结合表位的肽构象发生扭曲。